Results 121 to 130 of about 4,521 (193)

Upadacitinib in rheumatoid arthritis: progress and challenges. [PDF]

Front Pharmacol
Wang Q, Zhong L, Fu Y, Yang Z.
europepmc   +1 more source

Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications. [PDF]

Clin Exp Gastroenterol
Koivusalo M, Jokelainen J, Huhtinen A, Kovac B, Silvola S, Torvinen S, Ylisaukko-Oja T, Arkkila P.   +7 more
europepmc   +1 more source

Janus kinase inhibitors: another potential for uveitis treatment? [PDF]

Ann Eye Sci
Emami S, Kaisari E, Janetos TM.
europepmc   +1 more source

State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review. [PDF]

Pharmaceuticals (Basel)
Choi Y, Lee S, Kim HJ, Park T, Kwack WG, Yang S, Chung EK.   +6 more
europepmc   +1 more source

The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI. [PDF]

J Pers Med
Cassarà EAM, Marotto D, Bentivenga C, Martin Martin LS, Baldi G, Carrozzo N, Zicolella R, Terenzi R, Delle Sedie A, Benucci M.   +9 more
europepmc   +1 more source

Efficacy of Biologic Agents and Small Molecules for Endoscopic Improvement and Mucosal Healing in Patients with Moderate-to-Severe Ulcerative Colitis: Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Mademlis C, Katsoula A, Koufakis T, Paschos P, Kefas A, Teperikidis L, Theodoridou N, Giouleme O.   +7 more
europepmc   +1 more source

JAK Inhibitors and Risk of Cancer in IBD Patients. [PDF]

Cancers (Basel)
Bernardi F, Faggiani I, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D'Amico F.   +8 more
europepmc   +1 more source

Post-marketing surveillance of upadacitinib: multilevel analysis of venous thromboembolism reporting in global data and rheumatoid arthritis. [PDF]

Front Med (Lausanne)
Ferreira-da-Silva R, Lobo M, Abreu AR, Pereira-Macedo J, Mós B, Rodriguez CA, Lourenço IM, Vieira I, Polónia JJ, Gouveia L, Silva L, Morato M, Pinto M, Forrester M, Pereira M, Rodrigues N, Biase T, Ribeiro I.   +17 more
europepmc   +1 more source

Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. [PDF]

Inflamm Bowel Dis
Nakase H, Danese S, Reinisch W, Ritter T, Liang Y, Wendt E, Levesque BG, Yoon OK, Tian Y, Zhuo L, Karouzakis E, Bauer Y, Oortwijn A, Kaise T, Malkov VA, Hibi T.   +15 more
europepmc   +1 more source

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. [PDF]

Aliment Pharmacol Ther
Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M, GETAID‐J2J group.   +31 more
europepmc   +1 more source